论文部分内容阅读
目的比较研究化疗药物伊马替尼、柔红霉素和硼替佐咪对两种Ph(+)白血病细胞株K562(髓系白血病细胞株,表达P210蛋白)和SUP-B15(急性淋巴细胞白血病细胞株,表达P190蛋白)的抗肿瘤效应。方法采用MTT法测定不同浓度的伊马替尼、柔红霉素与硼替佐咪分别作用72 h后两种细胞株的增殖活性,并计算3种化疗药物对两种细胞株作用的半数抑制浓度(IC50);RT-PCR法检测不同浓度伊马替尼作用48 h后两种细胞株bcr-abl基因表达的改变。结果①不同浓度伊马替尼、柔红霉素与硼替佐咪分别作用K562和SUP-B15细胞株72h,其对细胞株的IC50值分别为(0.286±0.060)μmol/L、(0.303±0.009)μmol/L、(22.127±3.592)nmol/L和(1.387±0.180)μmol/L、(0.117±0.017)μmol/L、(12.35±0.740)nmol/L,提示伊马替尼对K562细胞敏感性明显高于SUP-B15细胞,而柔红霉素对SUP-B15更敏感,硼替佐咪对两种细胞的敏感性无差异;②伊马替尼0、0.35、1.0μmol/L作用48 h后,两株细胞bcr-abl基因表达均无明显变化。结论伊马替尼、柔红霉素、硼替佐咪对Ph(+)细胞株K562和SUP-B15均有较好的抗肿瘤效应,伊马替尼对K562更敏感,而柔红霉素和硼替佐咪对SUP-B15均有较好的抑制作用;短时间伊马替尼作用后不影响bcr-abl基因的表达。
Objective To compare the effects of chemotherapy drugs imatinib, daunorubicin and bortezomib on the proliferation of two Ph (+) leukemia cell lines K562 (myeloid leukemia cell line expressing P210 protein) and SUP-B15 (acute lymphoblastic leukemia cells Strain, expressing P190 protein). Methods MTT assay was used to determine the proliferative activity of the two cell lines after different concentrations of imatinib, daunorubicin and bortezomib for 72 h. The half inhibitory concentrations (IC50) of the three chemotherapeutic drugs against the two cell lines were calculated (IC50). The changes of bcr-abl gene expression in two cell lines were detected by RT-PCR 48 h after treatment with different concentrations of imatinib. Results ① IC50 values of imatinib, daunorubicin and bortezomib in K562 and SUP-B15 cell lines were (0.286 ± 0.060) μmol / L and (0.303 ± 0.009), respectively ), (22.127 ± 3.592) nmol / L and (1.387 ± 0.180) μmol / L, (0.117 ± 0.017) μmol / L and (12.35 ± 0.740) nmol / L, respectively, suggesting that imatinib is sensitive to K562 cells While that of daunorubicin was more sensitive to SUP-B15. There was no difference in the sensitivity of bortezomib between the two cell lines. (2) The effect of imatinib at 0, 0.35 and 1.0 μmol / L for 48 h After the two cells bcr-abl gene expression no significant change. Conclusion Imatinib, daunorubicin and bortezomib have better anti-tumor effect on Ph (+) cell lines K562 and SUP-B15, imatinib is more sensitive to K562, while daunorubicin and Bortezomib had a better inhibitory effect on SUP-B15; imatinib did not affect the expression of bcr-abl gene after a short time.